In response to the urgent need for new therapies that restore ventricular geometry and function, BioVentrix developed the Revivent System§ and the Revivent TC System*, both which facilitate Less Invasive Ventricular Enhancement™ (LIVE™). The Revivent Systems are simple, off-pump treatment options that are safer and less invasive than conventional surgical ventricular restoration. The LIVE procedure is beneficial because it:
Despite advances in percutaneous coronary intervention (PCI), approximately 35% of patients with acute coronary syndrome develop scar formation in the left ventricular for several reasons.1 To impact survival, PCI must be performed within the first 12 hours; however, 20% of patients seek intervention outside of this treatment window.2 As well, not all patients that receive PCI avoid scar formation; nearly 20% of PCI patients still develop scar that involves greater than a third of their LV mass.3
For thousands of patients across the European Union, scarred myocardium begins the adverse remodeling cycle of left ventricular dilatation. This increase in circumference and volume results in excessive wall tension, which triggers the progression of heart failure. For these patients, the Revivent Systems can provide an immediate reversal of the progression of the debilitating symptoms associated with heart failure.
The Revivent TC™ TransCatheter Ventricular Enhancement System requires regulatory approval and is not yet commercially available.
Mandelzweig et al. The Second Euro Heart Survey on Acute Coronary Syndromes: Characteristics, Treatment, and Outcome of Patients with ACS in Europe and the Mediterranean Basin in 2004, Eur Heart J. 2006;27:2285-2293.
Gibbons R et al. Acute PCI for ST-Segment Elevation Myocardial Infarction Is Later Better Than Never? JAMA. 2005;293(23):2930-31.
Stone G et al. Predictors of Infarct Size After Primary Coronary Angioplasty in Acute Myocardial Infarction from Pooled Analysis from Four Contemporary Trials. Am J of Cardiol. 2007;100(9):1370-75.